- Home
- FLNC vs WVE Comparison
FLNC vs WVE Comparison
Compare FLNC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- WVE
- Stock Information
- Founded
- FLNC 2018
- WVE 2012
- Country
- FLNC United States
- WVE Singapore
- Employees
- FLNC N/A
- WVE N/A
- Industry
- FLNC Industrial Machinery/Components
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- WVE Health Care
- Exchange
- FLNC Nasdaq
- WVE Nasdaq
- Market Cap
- FLNC 974.7M
- WVE 915.6M
- IPO Year
- FLNC 2021
- WVE 2015
- Fundamental
- Price
- FLNC $15.11
- WVE $7.18
- Analyst Decision
- FLNC Hold
- WVE Strong Buy
- Analyst Count
- FLNC 19
- WVE 14
- Target Price
- FLNC $10.44
- WVE $20.50
- AVG Volume (30 Days)
- FLNC 7.4M
- WVE 3.6M
- Earning Date
- FLNC 11-24-2025
- WVE 11-10-2025
- Dividend Yield
- FLNC N/A
- WVE N/A
- EPS Growth
- FLNC N/A
- WVE N/A
- EPS
- FLNC N/A
- WVE N/A
- Revenue
- FLNC $2,449,087,000.00
- WVE $109,230,000.00
- Revenue This Year
- FLNC N/A
- WVE N/A
- Revenue Next Year
- FLNC $20.89
- WVE $6.24
- P/E Ratio
- FLNC N/A
- WVE N/A
- Revenue Growth
- FLNC 14.26
- WVE 103.75
- 52 Week Low
- FLNC $3.46
- WVE $5.28
- 52 Week High
- FLNC $24.00
- WVE $16.38
- Technical
- Relative Strength Index (RSI)
- FLNC 42.47
- WVE 49.36
- Support Level
- FLNC $14.58
- WVE $6.60
- Resistance Level
- FLNC $18.28
- WVE $7.27
- Average True Range (ATR)
- FLNC 2.25
- WVE 0.53
- MACD
- FLNC -0.75
- WVE -0.04
- Stochastic Oscillator
- FLNC 9.06
- WVE 51.53
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.